Home | About Us | Cancer | For Patients | Locations | Links & Support | Billing/Insurance | Contact Us
Intensity Modulated Radiotherapy (IMRT) | Gamma Knifeļæ½ Radiosurgery
Prostate Brachytherapy | Vascular Brachytherapy | Radionuclide Treatment

Radionuclide Brachytherapy
Radionuclide therapy involves the use of a radiopharmaceutical - a drug that has a radioactive ingredient - for the diagnosis or treatment of disease. In radiation oncology, commonly used radionuclide therapies include the following:

  • QuadrametTM (Samarium-153) and MetastronTM (Strontium/Yttrium-90) for palliation of metastatic cancer to the bone. These agents, given as an outpatient injection, contain a radioisotope that is designed to target where the metastatic cells are attacking bones and avoid the normal areas of bone. These medicines are effective in relieving bony pain throughout the body, and they are particularly useful in treating cancers of the prostate, lung, and breast.

  • Radioactive Iodine (I-131) for the treatment of Thyroid Cancer and Hyperthyroidism/Graves' Disease.

  • ZevalinTM for the treatment of recurrent or refractory (unresponsive to conventional chemotherapy) non-Hodgkin's lymphoma. ZevalinTM, recently approved by the FDA, is the first of a new class of medicines known as radioimmunotherapy agents. Radioimmunotherapy is a promising new area of cancer treatment that combines the targeting power of monoclonal antibodies with the cell-killing ability of localized radiation.

Legal Disclaimer | Medical Information Policy | Privacy Policy
copryright © 2002 Florida Oncology Network, P.A.